South San Francisco, United States
NOETIK, founded in 2022, is carving a distinct niche in the biotech industry. Specializing in biotechnology and life sciences, this United States-based company is pioneering the use of AI to refine clinical outcomes in oncology. With its slogan, "Noetik is an AI-native biotech harnessing self-supervised learning to discover better precision immunotherapies," the company boasts a robust approach to developing precision immunotherapies utilizing self-supervised learning.
The company has developed foundational AI models using the largest proprietary multimodal human dataset in its field, facilitating precise matches of therapeutic targets to patient populations. This has led to strategic partnerships with clinical developers and notable pharmaceutical entities like GSK. Notably, NOETIK recently secured a $40.00M Series A investment on 01 August 2024, backed by a diverse pool of investors such as Breakout Ventures, EPIC Ventures, Zetta Venture Partners, and others. This investment underscores the significant confidence in the company's potential to revolutionize translational medicine and co-develop therapeutics with enhanced clinical success rates.
